



Sun Pharma Advanced Research Company Ltd.
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
CINNo:L73100GJ2006PLC047837

FOR IMMEDIATE RELEASE

SPARC/Sec/SE/2017-18/014

19th May 2017

To

The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited
P J Towers,
Dalal street,
Mumbai - 400001

Ref: *Scrip Code: NSE: SPARC; BSE: 532872*

Sub: *Update on Elepsia XRTM (Levetiracetam extended-release tablets 1000 mg and 1500 mg) NDA*

Dear Sir/Madam,

This is to inform you that, the Company has received a Complete Response Letter (CRL) from the USFDA for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg.

The CRL references the recent inspection of the Sun Pharmaceutical Industries Ltd.(SPIL)'s Halol manufacturing site by USFDA and indicates that, satisfactory resolution of the deficiencies identified during the inspection is required before the final approval of Elepsia XRTM can be granted.

SPARC had out-licensed Elepsia XRTM to a subsidiary of Sun Pharmaceutical Industries Ltd in July 2016.

As informed to the Company, SPIL is working with USFDA for resolving the cGMP deviations at the Halol facility and has taken several corrective measures.

This is for your information and public dissemination.

Yours faithfully,

For **Sun Pharma Advanced Research Company Limited**

Debashis Dey
Company Secretary